World's first drug against Bekhterev's disease

The Russian Ministry of Health has registered the world's first drug to treat Bekhterev's disease, which is rheumatoid spondyloarthritis, which is considered a chronic disease that affects the spine and the sacroiliac joint.

A report published by the ministry stated: “The Russian Ministry of Health registered the targeted and unique drug in the world to treat rheumatoid spondyloarthritis, and according to the results of clinical tests, the drug has shown high effectiveness and safety.”

The drug was developed by scientists from the Pirogov Russian National Medical Research University of the Russian Ministry of Health and the Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry in cooperation with the Russian pharmaceutical company BIOCAD.

The Ministry of Health indicated that the World Health Organization has given the drug the international designation seniprutug, and under this name information about the drug will be disseminated among medical and pharmaceutical workers around the world.

It is noteworthy that Bekhterev's disease is a chronic disease in which antibodies misidentify cartilage and joint tissue as foreign bodies, and pain and stiffness in the spine can lead to limited movement.

The developed drug allows the destruction of pathological T lymphocytes that attack the cells of the human body.

One of the drug developers, President of the Russian National Research Medical University Sergei Lukyanov, confirmed that the innovative drug helps stop the disease completely, has no immunosuppression and has no addictive effect.

The press service explained that after registering the drug, the drug manufacturing company can begin its industrial production.